Australasian COVID-19 Trial (ASCOT)
- Funded by Health Research Council of New Zealand
- Total publications:0 publications
Grant number: unknown
Grant search
Key facts
Disease
COVID-19Known Financial Commitments (USD)
$467,328.93Funder
Health Research Council of New ZealandPrincipal Investigator
Susan MorpethResearch Location
New Zealand, AustraliaLead Research Institution
Middlemore Clinical TrialsResearch Priority Alignment
N/A
Research Category
Clinical characterisation and management
Research Subcategory
Supportive care, processes of care and management
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Randomized Controlled Trial
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
ASCOT is an open label randomised controlled trial of unproven treatments for pandemic coronavirus infection among people unwell enough to need admission to hospital, but not so unwell that they need intensive care. Consenting participants will be randomised to either lopinavir-ritonavir (an anti-viral used to treat HIV), hydroxychloroquine (used in autoimmune diseases), both of these agents in combination, or the current standard of care. The study will be carried out at multiple sites across Australia and New Zealand. We will see whether either or both of these potential treatments will reduce the risk of needing intensive care or risk of death from pandemic coronavirus infection.